Patents by Inventor Wendy LIU

Wendy LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation and use of nanowrinkles
    Patent number: 8828302
    Abstract: Provided are methods of preparing a textured surface on a thermoplastic material that include treating the material with a plasma and subsequently shrinking the substrate to induce formation of textures.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: September 9, 2014
    Assignee: The Regents of the University of California
    Inventors: Michelle Khine, Cheng-Wei Aaron Chen, Wendy Liu, Tingting Wang
  • Pricing and forecasting
    Patent number: 8676632
    Abstract: The pricing of a product is programmatically defined as a solution to a price optimization equation that includes an in-date constraint and an out-date constraint. The in-date constraint may require that the price established by the price optimization equation be predicted not to exhaust an inventory of the product during a first time interval. The out-date constraint may require that the same price established by the price optimization equation be predicted to exhaust an inventory of the product by the end of a second time interval.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Overstock.com, Inc.
    Inventors: Angela Watson, Rebecca Richardson, Anshu Jalora, Wendy Liu, Ryan Hofmann
  • IMMUNOMODULATORY MATERIALS FOR IMPLANTABLE MEDICAL DEVICES
    Publication number: 20140072603
    Abstract: The present invention relates to biomaterials that interact with and regulate immune functions, as well as implantable materials and devices. In one embodiment, the present invention provides an implantable medical device comprising a biomaterial coated with one or more CD200 molecules. In another embodiment, the present invention provides a method of treating inflammation by administering a composition comprising one or more biomaterials that inhibit immune reactivity.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 13, 2014
    Applicant: The Regents of the University of California
    Inventors: Wendy Liu, Yoon Kyung Kim
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20140038939
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: October 9, 2013
    Publication date: February 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
  • Triazolopyridine JAK inhibitor compounds and methods
    Patent number: 8609687
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: December 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120264747
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 18, 2012
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Wendy Liu
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120225855
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
  • PREPARATION AND USE OF NANOWRINKLES
    Publication number: 20120200008
    Abstract: Provided are methods of preparing a textured surface on a thermoplastic material that include treating the material with a plasma and subsequently shrinking the substrate to induce formation of textures.
    Type: Application
    Filed: February 6, 2012
    Publication date: August 9, 2012
    Inventors: Michelle KHINE, Cheng-Wei Aaron CHEN, Wendy LIU, Tingting WANG
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120190665
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: July 2, 2010
    Publication date: July 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark Zak, Aihe Zhou, Bing-Yan Zhu
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20100035875
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 19, 2009
    Publication date: February 11, 2010
    Inventors: Bing-Yan ZHU, Michael SIU, Steven R. MAGNUSON, Richard PASTOR, He HAIYING, Xiao YISONG, Zheng JIFU, Xu XING, Zhao JUNPING, Wendy LIU